Drugs / L-Leucine
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 25 trials · 2 missed | ||||||
| Phase 2 | NCT07647003 | Oct 2026 → May 2027 expected | hypertensive disorder | NuSirt Biopharma | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06580145 | Feb 2025 → Jun 2028 expected | major depressive disorder | Emory University | Recruiting | No outcome recorded |
| Phase 2 | NCT03079297 | Mar 2017 → Oct 2021 | major depressive disorder | University of Texas Southwestern Medical Center | Terminated | Missed primary |
| Phase 2 | NCT02435277 | Oct 2014 → Sep 2015 | type 2 diabetes mellitus | NuSirt Biopharma | Completed | Missed primary |
| Phase 2 | NCT02386267 | Sep 2014 → Mar 2015 | Diamond-Blackfan anemia | Federal Scientific Clinical Centre of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogache | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT01208324 Comparator | Mar 2010 → Nov 2018 | premature menopause | University of Colorado, Denver | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-Leucine | “Two tablets 550 mg L-leucine + 250 mg metformin and one tablet 1.0 mg sildenafil per dose; 3 tablets/dose orally BID” NCT07647003 ↗5“3 capsules BID with each capsule containing 366.7 mg L-Leucine and 41.7 mg of metformin” NCT02435277 ↗ “L-Leucine (6.6 g)” NCT01208324 ↗ |
| Action | Inhibit | “competitively inhibit kynurenine uptake into the brain” NCT06580145 ↗ |
| Modality | Small molecule | “There are some indications that the Amino Acid (AA) L-leucine, a translation enhancer, may have some efficacy in DBA and 5q-syndrome” NCT02386267 ↗ |
| Route | Oral | “Each test day will involve the ingestion of 70 capsules.” NCT01208324 ↗ |